Ponatinib-Related Vasospastic Angina-Reference-Cited by-同舟云学术

Ponatinib-Related Vasospastic Angina

Published:2024-03-30 Issue:2 Volume:65 Page:349-353
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Shindo Michiho¹²,Komiyama Chinatsu¹,Yamaguchi Tetsuo¹,Kageyama Kosei²,Yamamoto Hisashi²,Fujimoto Yo¹,Uchida Naoyuki²,Kodama Takahide¹

Affiliation:

1. Department of Cardiology, Toranomon Hospital

2. Department of Hematology, Toranomon Hospital

Publisher

International Heart Journal (Japanese Heart Journal)

Link

https://www.jstage.jst.go.jp/article/ihj/65/2/65_23-355/_pdf

Reference8 articles.

1. 1. Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell 2020; 37: 530-42.

2. 2. Cortes JE, Kim D, Pinilla-Ibarz J, et al. ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132: 393-404.

3. 3. Jain J, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood 2019; 3: 851-61.

4. 4. Valent P, Hadzijusufovic E, Hoermann G, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res 2017; 59: 47-54.

5. 5. Fiets RB, Staal AHJ, Blijlevens NMA. Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia. Neth J Med 2018; 76: 330-5.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Risk Factors Predicting Cardiovascular and Cancer Deaths in a Middle-Aged Population Followed-Up for 61 Years until Extinction;Journal of Cardiovascular Development and Disease;2024-08-05

2. Multiple drugs;Reactions Weekly;2024-06-08